The pharmacological inhibition of DDAH1 is emerging as an attractive therapeutic strategy in disease states, e.g., septic shock and cancer, that are characterized by excessive local and/or systemic NO synthesis, primarily mediated by the inducible NOS isoform (iNOS) [9,10,11,12,13,14]. Here, DDAH1 is linked to cancer.